Brittany Gouse, MD, MPH
Assistant Professor, Psychiatry
Biography
Dr. Brittany Gouse’s MD MPH is the Assistant Director of Boston Medical Center (BMC)’s specialty psychosis clinic, the Wellness and Recovery After Psychosis (WRAP) program, and Assistant Professor of Psychiatry at Boston University (BU) Chobanian & Avedisian School of Medicine. She completed a joint MD/MPH degree through the SUNY Upstate Medical University/Syracuse University and her residency in adult psychiatry and fellowship in Public Psychiatry at BU/BMC. Her fellowship focus was on the care of individuals living with schizophrenia and other forms of psychotic illness. Clinically she sees patients in WRAP program and specializes in clozapine and long-acting injectable antipsychotic treatment.
Dr. Gouse’s clinical and research focus is on schizophrenia. She is a psychiatric epidemiologist whose research broadly focuses on modifiable factors that drive the 15-20 year mortality gap in schizophrenia. She was selected for the BU Clinical and Translational Science Institute KL2 Career Development Award (2023-2025) and the American Psychiatric Association Research Fellowship (2023-2025). She founded the Advancing Coordinated Care through Epidemiologic Studies (ACCESS) Initiative, which aims to improve outcomes in early psychosis through electronic health record and geocoding data.
Her advocacy efforts are focused on increasing access to evidence-based treatment in the early psychosis period, particularly the early use of long-acting injectable antipsychotics and clozapine to reduce the risk of premature mortality following the onset of psychosis. She served on the APA Council on Research (2023-2025) as a fellow member and as a Chair of the Public Sector Commitee of the Massachusetts Psychiatric Society (2021-2023).
Other Positions
- Psychiatrist, Psychiatry, Boston Medical Center
Education
- State University of New York Upstate Medical University, MD/MPH
- Tulane University, BS
Publications
- Published on 1/11/2025
Boliver EE, Gouse BM, Baul TD, Agarwal N, Blanton AC, Lancet J, Xu C, Brown HE. Prolonged length of stay among individuals presenting to the emergency department with psychosis: Associations with sociodemographic and visit-level characteristics. J Psychiatr Res. 2025 Feb; 182:391-397. PMID: 39862766.
Read at: PubMed - Published on 4/10/2024
Gouse BM, Oblath R, Gibbs JS, Reagan EG, Brown HE. COVID-19 pandemic and emergency department visits for psychosis: Visit volume, restraint use, medication use, psychiatric hospitalization, and length of stay. Schizophr Res. 2024 May; 267:301-307. PMID: 38603838.
Read at: PubMed - Published on 3/4/2024
Gouse BM, Weinberg JM, Brown HE. Risk Stratification to Reduce Excess Mortality in Early Psychosis. JAMA Netw Open. 2024 Mar 04; 7(3):e240623. PMID: 38497967.
Read at: PubMed - Published on 4/20/2023
Gouse BM, Schwarz AG, Gibbs JS, Weinberg JM, Yue H, Chava A, Brown HE. Demographic predictors of lack of current mental health treatment among university students with a schizophrenia spectrum disorder. Early Interv Psychiatry. 2023 Dec; 17(12):1207-1215. PMID: 37081818.
Read at: PubMed - Published on 3/20/2023
Gouse BM, Boliver EE, Oblath R, Camacho L, Brown HE. Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits. Psychiatry Res. 2023 May; 323:115151. PMID: 36934468.
Read at: PubMed - Published on 3/17/2023
Gouse BM, Boliver EE, Oblath R, Camacho L, Brown HE. Cannabis use among patients presenting to the emergency department for psychosis: Associations with restraint use, medication administration, psychiatric hospitalization, and repeat visits. Psychiatry Res. 2023 Mar 17; 323:115151. PMID: 36934468.
Read at: PubMed - Published on 1/9/2023
Gouse BM, Kline ER. Clinical insights: Preventing psychosis treatment disengagement. Schizophr Res. 2023 Feb; 252:64-66. PMID: 36628870.
Read at: PubMed - Published on 7/1/2022
Gouse BM, Brown HE. Improving Outcomes in Schizophrenia-A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness. JAMA Netw Open. 2022 Jul 01; 5(7):e2224172. PMID: 35900769.
Read at: PubMed - Published on 6/6/2022
Schor SH, Gibbs JS, Gouse BM, Brown HE. A call to action: Increased mortality from COVID-19 among individuals with schizophrenia calls for coordinated vaccination efforts. Schizophr Res. 2022 Aug; 246:63-64. PMID: 35716577.
Read at: PubMed - Published on 2/19/2021
Gouse BM, Nieves-Archibald A, Trutzer I, Rezvani M, Srinath M, Chang A, Wilensky D, Duncan A. Pediatric Malignant Catatonia Associated With Vaporized Cannabis Use: A Case Series. J Acad Consult Liaison Psychiatry. 2021 Jul-Aug; 62(4):445-448. PMID: 34210403.
Read at: PubMed
View 9 more publications: View full profile at BUMC